NEW YORK, June 30, 2016 /PRNewswire/ -- Amid the unsafe
domestic vaccine events, China's
human vaccine lot release volume in 2015 fell by 17.9% year on year
to only 650 million doses,touching a 5-year low. Moreover, with the
improvements in domestic vaccine supply capacity and vaccine
circulation safety, China's human
vaccine import volume has showed a year-by-year decline in recent
years, with the imports for 2015 totaling 173.9 tons, down 17.5%
year on year.
Affected by China's
less-developed economy, existing national vaccine prevention
policies and people's awareness of epidemic prevention, free EPI
vaccines prevail in China. But the
market share is falling, with the free EPI vaccine lot release
volume in 2015 accounting for about 74.3% of the total. The Chinese
free human vaccine market is still dominated by the subsidiaries of
China National Biotec Group—including Beijing Tiantan Biological
Products, Chengdu Institute of Biological Products Co., Ltd.,
Shanghai Institute of Biological Products Co., Ltd., Lanzhou
Institute of Biological Products Co., Ltd., Wuhan Institute of
Biological Products Co., Ltd., and Changchun Institute of
Biological Products Co., Ltd.—and state-owned enterprises like
Institute of Medical Biology under Chinese Academy of Medical
Sciences. In 2015, the EPI vaccine lot release volume of Chinese
state-owned enterprises made up 72.6% of the total.
However, as China gradually
relaxes controls on the vaccine market, private companies have
unexpectedly emerged in extra EPI vaccine market segment in recent
years, with the proportion increasing constantly. In 2015, their
lot release volume accounted for 70% in this market segment.
Furthermore, these enterprises hold a dominant position in
haemophilus influenza B (Hib), human rabies vaccine, varicella
vaccine, influenza vaccine, and other market segments.
Being upbeat about China's
human vaccine demand market and exports, many vaccine producers are
stepping up vaccine R&D or expanding capacity.
So far, there are four enterprises in China, namely Walvax Biotechnology, Beijing
Minhai Biotechnology, SINOVAC BIOTECH, and Lanzhou Institute of
Biological Products, whose 13-valent pneumococcal conjugate vaccine
(PCV13) have entered clinical research stage; recombinant HPV
vaccines, developed by Shanghai Zerun Biotechnology, a subsidiary
of Walvax Biotechnology, and Xiamen Innovax Biotech, have entered
phase III clinical research phase.
In 2015, CFDA approved the production and registration
application of the world's first inactivated Sabin strain polio
vaccine, which was developed by the Institute of Medical Biology of
the Academy of Medical Sciences. The vaccine was brought to market
on June 30, 2015. Over the same year,
the inactivated enterovirus 71 (EV71) vaccines (for hand-foot-mouth
disease prevention), also developed by the Institute of Medical
Biology of the Academy of Medical Sciences was made available after
the approval from CFDA; SINOVAC BIOTECH and Wuhan Institute of
Biological Products are applying for drug production license of
inactivated enterovirus 71 (EV71) vaccines; Hualan Bio and Beijing
ZhifeiLvzhu Biopharmaceutical (a subsidiary of Chongqing Zhifei
Biological Products) have submitted the application of clinic trial
of inactivated enterovirus 71 (EV71) vaccines.
China Human Vaccine Industry Report, 2016-2020 highlights the
following:
Operating environment, overall situation, sales channel, etc. of
China human vaccine industry;
Supply & demand, competitive landscape, import & export,
and development forecast of the Chinese human vaccine market;
Supply & demand, competitive landscape, and market prices of 10
vaccine product segments in China,
including hepatitis B vaccine, influenza vaccine, rabies vaccine,
and pneumococcal vaccine;
Operation, vaccine business, and development prospects of 16
Chinese human vaccine companies.
Read the full report:
http://www.reportlinker.com/p0512477-summary/view-report.html
About Reportlinker
ReportLinker is an award-winning market research solution.
Reportlinker finds and organizes the latest industry data so you
get all the market research you need - instantly, in one
place.
http://www.reportlinker.com
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/china-human-vaccine-industry-report-2016-2020-300293062.html
SOURCE Reportlinker